BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tao L, Zhang H, An G, Lan H, Xu Y, Ge Y, Yao J. Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:739263. [PMID: 34722290 DOI: 10.3389/fonc.2021.739263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang L, Jin G, Li D. Tat-hspb1 Suppresses Clear Cell Renal Cell Carcinoma (ccRCC) Growth via Lysosomal Membrane Permeabilization. Cancers 2022;14:5710. [DOI: 10.3390/cancers14225710] [Reference Citation Analysis]
2 Zhao F, Yu R, Chen S, Zhao S, Sun L, Xu Z, Zhang Y, Dai S, Zhang G, Shu Q. Global research trends on precision cancer medicine-related rashes (2008-2021): A bibliographic study. Front Immunol 2022;13:1002034. [DOI: 10.3389/fimmu.2022.1002034] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Xiao Y, Yang J, Yang M, Len J, Yu Y. Comprehensive analysis of 7-methylguanosine and immune microenvironment characteristics in clear cell renal cell carcinomas. Front Genet 2022;13:866819. [DOI: 10.3389/fgene.2022.866819] [Reference Citation Analysis]